查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1714720

细胞株开发市场：按类型、按产品、按来源、按应用、按最终用户 - 2025-2030 年全球预测

Cell Line Development Market by Type, Offerings, Source, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2024 年细胞株开发市场将达到 108.7 亿美元，到 2025 年将达到 119.1 亿美元，到 2030 年将达到 189.6 亿美元，复合年增长率为 9.70%。

细胞株开发基础知识与背景介绍

主要市场统计数据
基准年2024年 108.7亿美元
预计2025年 119.1亿美元
预测年份 2030 189.6亿美元
复合年增长率（%） 9.70%

细胞株开发已成为现代生物技术的重要支柱，推动了药物发现、生物生产、毒性测试和组织工程的创新。该领域的快速发展不仅重新定义了研究和製造格局，而且为寻求利用其潜力的现有企业和新兴企业提供了变革机会。

最近的趋势表明，技术进步和更深入的科学理解正在彻底改变细胞株的开发和使用方式。这项进步体现在改进的特性描述技术和复杂的客自订开发策略上，从而提高了效率和可靠性。随着产业的发展，了解应对竞争环境所需的多方面方法至关重要。这份第一份简报重点在于从传统方法到下一代方法的演变，为在日益复杂的市场中做出明智的决策提供了重要见解。

目前的市场格局以消费者需求、监管环境和技术创新的动态变化为特征。了解历史背景和新兴趋势将使相关人员能够更好地预测市场需求，并从策略上定位自己以利用这些机会。

改变细胞株开发市场

在科学创新和不断变化的客户需求的推动下，细胞株开发领域发生了重大的结构性变化。现代研究协议严重依赖自动化、高通量筛检和预测分析，从而提高以前无法实现的效率。这些进步正在改变产品的开发、评估和商业化方式。

另一个关键驱动因素是向自订细胞株开发与综合表征服务相结合的整合解决方案的转变。这种方法简化了工作流程，缩短了产品上市时间，并使公司能够快速回应新兴的治疗趋势。同时，对高效能生物加工设备和消耗品的需求激增也凸显了价值链各环节中嵌入式技术创新的重要性。

市场竞争者越来越多地转向联合研究和策略伙伴关係，以获取新技术、扩大产品系列併提高竞争地位。这种不断变化的环境需要积极主动的思考，并强调敏捷性和策略远见的重要性，以利用这些变革趋势带来的好处。

塑造深度市场的关键细分洞察

多方面的细分框架是了解细胞株开发市场的核心。从产品类型的角度检验此领域，市场大致分为连续细胞株和有限细胞株。经过仔细分析，连续细胞株进一步细分为融合瘤和干细胞株，突显了生物系统的复杂性及其目前应用的特殊性。

同样，市面上有各种解决方案，包括细胞株服务、消耗品、设备、培养基和试剂。细胞株服务部门区分细胞株表征服务和客自订细胞株开发，使服务供应商能够满足小众需求。在设备领域，生物反应器和培养箱的重要性得到强调，它们对于维持最佳生长条件和提高製程效率至关重要。

基于来源以及产品或服务的细分提供了进一步的清晰度，市场区分为哺乳动物和非哺乳动物模型。例如，非哺乳动物类别包括两栖类和昆虫系统，每种系统都提供独特的生物学见解。基于应用的细分进一步突显了市场的广度，涵盖了生物生产、药物发现、研究和开发、组织工程和毒性测试等领域。最后，当谈到最终用户时，市场在生物技术公司、製药公司和研究机构之间存在差异，每家公司都为该行业带来不同的需求和挑战。

这些细分洞察提供了市场结构的全面视图，使相关人员能够更精确地调整其策略以适应不断变化的趋势和特定的最终用户需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 细胞株开发对CDMO服务的需求不断增长
      • 单株抗体需求的增加导致细胞株开发市场的成长
      • 增加疫苗产量
    • 限制因素
      • 降低细胞株开发中的吞吐量和污染问题
    • 机会
      • 研发投入激增推动细胞株生成技术进步
      • 3D细胞培养的创新为药物发现和开发过程带来了新的机会
    • 任务
      • 与细胞株开发相关的选择中存在高度偏见的担忧
  • 市场区隔分析
    • 类型：在适当的培养条件下无限生长的持续生长细胞株类型
    • 我们提供的：增加培养基和试剂的使用以支持细胞维护和下游应用
    • 来源：利用能忠实模仿人类细胞功能的哺乳动物细胞株
    • 应用：优先考虑再生医学和个人化治疗的组织工程
    • 最终用户：希望开发优先考虑速度和客製化流程的细胞株的生物技术公司
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章细胞株开发市场（按类型）

  • 常用细胞株
    • 融合瘤
    • 干细胞株
  • 有限细胞株

第七章细胞株开发市场：依供应情况

  • 细胞株服务
    • 细胞株表征服务
    • 自订细胞株开发
  • 耗材
  • 装置
    • 生物反应器
    • 孵化器
  • 培养基和试剂

第八章细胞株开发市场：依来源

  • 哺乳动物
  • 非哺乳动物
    • 两栖类
    • 昆虫

第九章细胞株开发市场：依应用

  • 生物生产
  • 药物研发
  • 研究与开发
  • 组织工程
  • 毒性测试

第 10 章细胞株开发市场（依最终用户）

  • 生技公司
  • 製药公司
  • 研究机构

第 11 章美洲细胞株开发市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太细胞株开发市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲细胞株开发市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Advanced Instruments, LLC
  • AGC Group
  • Ajinomoto Co., Inc
  • Akadeum Life Sciences, Inc.
  • Aragen Life Sciences Ltd.
  • Avioq, Inc.
  • Catalent, Inc. by Novo Holdings A/S
  • Charles River Laboratories International, Inc.
  • Corning Incorporated
  • Cyagen Biosciences, Inc.
  • Danaher Corporation
  • EuBiologics Co.,Ltd.
  • Eurofins Scientific SE
  • FUJIFILM Diosynth Biotechnologies
  • GenScript Biotech Corporation
  • KBI Biopharma, Inc.
  • Lonza Group AG
  • Merck Group
  • PromoCell GmbH
  • Rentschler Biopharma SE
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • WuXi Biologics Co., Ltd.
Product Code: MRR-43078BB92CCA

The Cell Line Development Market was valued at USD 10.87 billion in 2024 and is projected to grow to USD 11.91 billion in 2025, with a CAGR of 9.70%, reaching USD 18.96 billion by 2030.

Foundation and Context: Introduction to Cell Line Development

KEY MARKET STATISTICS
Base Year [2024] USD 10.87 billion
Estimated Year [2025] USD 11.91 billion
Forecast Year [2030] USD 18.96 billion
CAGR (%) 9.70%

Cell line development has emerged as a critical pillar in modern biotechnology, propelling innovations in drug discovery, bioproduction, toxicology testing, and tissue engineering. The rapid advancements in this sector have not only redefined the research and manufacturing landscape but also offered transformative opportunities for both established companies and emerging entities looking to harness its potential.

In recent years, technological improvements and increased scientific understanding have reformed how cell lines are developed and utilized. This progression is reflected by enhanced characterization techniques and refined custom development strategies that boost both efficiency and reliability. As the industry evolves, it is imperative to appreciate the multi-faceted approach required to navigate the competitive environment. This initial overview lays the groundwork by highlighting the evolution from conventional methodologies to next-generation practices, offering insights that are crucial for making informed decisions in an increasingly complex market.

The current market landscape is characterized by dynamic shifts in consumer demand, regulatory environments, and technological breakthroughs. By understanding the historical context paired with emerging trends, stakeholders can better anticipate market needs and strategically position themselves to capitalize on these opportunities.

Transformative Shifts in the Cell Line Development Landscape

The cell line development arena has experienced significant structural changes fuelled by scientific innovation and evolving customer requirements. Modern research protocols are heavily reliant on automation, high-throughput screening, and predictive analytics to drive efficiencies that were previously unattainable. These advancements are transforming how products are developed, evaluated, and commercialized.

Another critical factor is the shift towards integrated solutions that blend custom cell line development with comprehensive characterization services. Such an approach streamlines workflows and reduces time-to-market, positioning companies to respond rapidly to emerging therapeutic trends. In parallel, a surge in demand for efficient bioprocessing equipment and consumables further exemplifies the integration of technological innovations into every segment of the value chain.

Market players are increasingly leveraging collaborations and strategic partnerships to access novel technologies, expand their product portfolios, and strengthen their competitive positioning. This environment of constant change requires a proactive mindset, underscoring the importance of agility and strategic foresight in harnessing the benefits of these transformative trends.

Deep Dive: Key Segmentation Insights Shaping the Market

A multifaceted segmentation framework is at the heart of understanding the cell line development market. When examining the field from a product type perspective, the market is broadly divided into continuous cell lines and finite cell lines. A more intricate analysis reveals that continuous cell lines are further segmented into hybridomas and stem cell lines, emphasizing the complexity of biological systems and the specialized nature of current applications.

Similarly, the offerings within the market encompass a variety of solutions, including cell line services, consumables, equipment, and media and reagents. The cell line services segment itself distinguishes between cell line characterization services and custom cell line development, allowing service providers to target niche requirements. Equipment segmentation underlines the importance of bioreactors and incubators, which are pivotal for maintaining optimal growth conditions and enhancing process efficiencies.

Beyond the products and services, segmentation based on source provides additional clarity, with the market differentiating between mammalian and non-mammalian models. The non-mammalian category, for example, includes both amphibian and insect systems, each offering unique biological insights. The application-based segmentation further underscores the breadth of the market by covering domains such as bioproduction, drug discovery, research and development, tissue engineering, and toxicity testing. Finally, when targeting end users, the market is differentiated among biotechnology companies, pharmaceutical companies, and research institutes, each bringing diverse needs and challenges to the sector.

Together, these segmentation insights provide a comprehensive view of the market's structure, enabling stakeholders to align their strategies more precisely with evolving trends and specific end-user demands.

Based on Type, market is studied across Continuous Cell Lines and Finite Cell Lines. The Continuous Cell Lines is further studied across Hybridomas and Stem Cell Lines.

Based on Offerings, market is studied across Cell Line Services, Consumables, Equipment, and Media & Reagents. The Cell Line Services is further studied across Cell Line Characterization Services and Custom Cell Line Development. The Equipment is further studied across Bioreactors and Incubator.

Based on Source, market is studied across Mammalian and Non-Mammalian. The Non-Mammalian is further studied across Amphibian and Insect.

Based on Application, market is studied across Bioproduction, Drug Discovery, Research & Development, Tissue Engineering, and Toxicity Testing.

Based on End User, market is studied across Biotechnology Companies, Pharmaceutical Companies, and Research Institutes.

Regional Perspectives: Heterogeneity and Growth Across Global Markets

The geographical dimension of the cell line development market reveals considerable variations in market maturity, regulatory frameworks, and technology adoption. In the Americas, the market benefits from robust research ecosystems, substantial investments in biotechnological innovations, and strong collaboration between academic institutions and industry leaders. Such an environment has paved the way for rapid advancements, making it a crucial hub for both research and commercial applications.

Turning to the combined region of Europe, the Middle East, and Africa, a diverse range of economies is observed. In Europe, the presence of stringent regulatory standards coexists with cutting-edge research facilities, fostering an environment where quality and innovation are paramount. In contrast, emerging markets in the Middle East and Africa are beginning to leverage these technologies as they invest in new infrastructure and foster skills development. These mixed dynamics highlight an evolving landscape where traditional practices are being supplemented by modern methodologies.

Across the Asia-Pacific, rapid industrial growth and increasing investments in scientific research are the primary catalysts driving market expansion. The region's commitment to enhancing its technological capabilities is evident through significant government initiatives and partnerships with leading research institutions. This globally distributed progression emphasizes that while the demand drivers may vary by region, the underlying impetus for adopting advanced cell line development technologies is universally strong.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Edge: Illuminating Key Players in the Market

An in-depth analysis of the competitive environment reveals a spectrum of influential companies that are shaping the market trajectory in cell line development. Noteworthy among these are Advanced Instruments, LLC and AGC Group, who have consistently pushed boundaries by integrating innovative solutions with high-quality service offerings. Organizations such as Ajinomoto Co., Inc and Akadeum Life Sciences, Inc. have extended their global footprints by leveraging their scientific expertise to meet diverse market needs.

Aragen Life Sciences Ltd. and Avioq, Inc. have also made significant contributions, with their strategic focuses enhancing both research capabilities and operational efficiencies. Catalent, Inc. by Novo Holdings A/S and Charles River Laboratories International, Inc. play pivotal roles in streamlining development processes from conceptualization to production. Equally notable are Corning Incorporated and Cyagen Biosciences, Inc., whose contributions have refined the methodologies and tools employed in research environments.

The list of companies extends further to include renowned entities such as Danaher Corporation, EuBiologics Co.,Ltd., and Eurofins Scientific SE, each of which has successfully adapted to emerging trends while catering to an international clientele. Brands like FUJIFILM Diosynth Biotechnologies, GenScript Biotech Corporation, and KBI Biopharma, Inc. contribute significantly by integrating state-of-the-art technologies into their service models. In addition, the prominence of Lonza Group AG, Merck Group, PromoCell GmbH, and Rentschler Biopharma SE is reinforced by their commitment to quality and innovation. Prominent market leaders such as Samsung Biologics Co., Ltd., Sartorius AG, Syngene International Limited, Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., and WuXi Biologics Co., Ltd. further underscore the competitive spirit and dynamic progress defining the market today.

The report delves into recent significant developments in the Cell Line Development Market, highlighting leading vendors and their innovative profiles. These include Advanced Instruments, LLC, AGC Group, Ajinomoto Co., Inc, Akadeum Life Sciences, Inc., Aragen Life Sciences Ltd., Avioq, Inc., Catalent, Inc. by Novo Holdings A/S, Charles River Laboratories International, Inc., Corning Incorporated, Cyagen Biosciences, Inc., Danaher Corporation, EuBiologics Co.,Ltd., Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies, GenScript Biotech Corporation, KBI Biopharma, Inc., Lonza Group AG, Merck Group, PromoCell GmbH, Rentschler Biopharma SE, Samsung Biologics Co., Ltd., Sartorius AG, Syngene International Limited, Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., and WuXi Biologics Co., Ltd.. Strategic Recommendations for Forward-Thinking Industry Leaders

For industry leaders seeking to maintain a competitive edge in the evolving landscape of cell line development, several strategic recommendations come to the forefront. First and foremost is the adoption of integrated development platforms that combine advanced characterization techniques with bespoke cell line development services. This approach ensures that companies can rapidly adapt to scientific advancements and streamline the transition from concept to commercialization.

Investing in state-of-the-art bioprocess automation and monitoring technologies has also proven crucial. By leveraging these tools, organizations can gain deeper insights into process variability and improve overall production efficiency. Furthermore, it is essential for companies to foster strategic alliances, both domestically and internationally, to tap into emerging markets and diversify their technological competencies.

Another core recommendation is the customization of product offerings to suit regional demands and application-specific requirements. By tailoring solutions to meet the precise needs of biotechnology companies, pharmaceutical firms, and research institutes, businesses can better secure their market position. Finally, building strong research collaborations and continuously investing in talent is critical for navigating regulatory challenges and embracing the rapid pace of technological change.

Summarizing the Imperatives in Cell Line Development

In conclusion, the cell line development market is characterized by dynamic changes and multifaceted segmentation that encapsulate its vast growth potential. Technological advancements, combined with evolving regional and application-specific demands, have redefined the competitive landscape. Stakeholders are now challenged with capitalizing on innovation while ensuring that robust strategies are in place to handle regulatory and market complexities.

By understanding and leveraging key segmentation insights, regional nuances, and competitive intelligence, industry leaders can chart a course that not only safeguards but also enhances their market presence. A concerted focus on integrated solutions, technological investment, and strategic partnerships will be vital in sustaining progress and driving future success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising need for CDMO services for cell line development
      • 5.1.1.2. Increasing need for monoclonal antibodies bolstering the cell line development market
      • 5.1.1.3. Growing rise in vaccine production
    • 5.1.2. Restraints
      • 5.1.2.1. Low throughput and contamination concerns in cell line development
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in investments in research and development promoting advancements in cell line creation
      • 5.1.3.2. Innovations in 3D cell culture open new opportunities in drug discovery and development processes
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with high potential in selection of bias associated with the cell line development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising continuous cell lines type to proliferate indefinitely under proper culture conditions
    • 5.2.2. Offerings: Growing usage of media & reagents to support cell maintenance and downstream applications
    • 5.2.3. Source: Utilization of mammalian cell lines for their ability to closely mimic human cellular functions
    • 5.2.4. Application: Preference for tissue engineering for regenerative medicine and personalized therapies
    • 5.2.5. End User: Adaption of biotechnology companies for cell line development to emphasize speed, and customized processes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell Line Development Market, by Type

  • 6.1. Introduction
  • 6.2. Continuous Cell Lines
    • 6.2.1. Hybridomas
    • 6.2.2. Stem Cell Lines
  • 6.3. Finite Cell Lines

7. Cell Line Development Market, by Offerings

  • 7.1. Introduction
  • 7.2. Cell Line Services
    • 7.2.1. Cell Line Characterization Services
    • 7.2.2. Custom Cell Line Development
  • 7.3. Consumables
  • 7.4. Equipment
    • 7.4.1. Bioreactors
    • 7.4.2. Incubator
  • 7.5. Media & Reagents

8. Cell Line Development Market, by Source

  • 8.1. Introduction
  • 8.2. Mammalian
  • 8.3. Non-Mammalian
    • 8.3.1. Amphibian
    • 8.3.2. Insect

9. Cell Line Development Market, by Application

  • 9.1. Introduction
  • 9.2. Bioproduction
  • 9.3. Drug Discovery
  • 9.4. Research & Development
  • 9.5. Tissue Engineering
  • 9.6. Toxicity Testing

10. Cell Line Development Market, by End User

  • 10.1. Introduction
  • 10.2. Biotechnology Companies
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutes

11. Americas Cell Line Development Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cell Line Development Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cell Line Development Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. PHC and CCRM team up to transform T-cell culture processes for CGT manufacturing
    • 14.3.2. BioCina and NovaCina merger fuels global CDMO leadership
    • 14.3.3. GMP-Quality iPSC line to accelerate advanced therapies
    • 14.3.4. Altaris expands its cell therapy footprint through strategic acquisition
    • 14.3.5. NewBiologix unveils Xcell rAAV platform to accelerate gene therapy development
    • 14.3.6. Scorpius Holdings partners with Celltheon Corp to advance cell line development
    • 14.3.7. Catalent and IsomAb accelerate ISM-001 development
    • 14.3.8. WuXi Biologics introduced WuXia RidGS, a pioneering platform for non-antibiotic cell line development
    • 14.3.9. Samsung Biologics launches next-gen platforms for enhanced therapeutic efficacy
    • 14.3.10. Asimov launches lentiviral production with stable cell line service
    • 14.3.11. FUJIFILM Corporation announced a USD 1.2 billion investment to expand its cell culture CDMO business
    • 14.3.12. Ajinomoto CELLiST Korea launches CELLiST F7 for enhanced CHO cell productivity
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Sartorius AG
    • 14.4.2. Thermo Fisher Scientific Inc.
    • 14.4.3. WuXi Biologics Co., Ltd.
    • 14.4.4. Lonza Group AG

Companies Mentioned

  • 1. Advanced Instruments, LLC
  • 2. AGC Group
  • 3. Ajinomoto Co., Inc
  • 4. Akadeum Life Sciences, Inc.
  • 5. Aragen Life Sciences Ltd.
  • 6. Avioq, Inc.
  • 7. Catalent, Inc. by Novo Holdings A/S
  • 8. Charles River Laboratories International, Inc.
  • 9. Corning Incorporated
  • 10. Cyagen Biosciences, Inc.
  • 11. Danaher Corporation
  • 12. EuBiologics Co.,Ltd.
  • 13. Eurofins Scientific SE
  • 14. FUJIFILM Diosynth Biotechnologies
  • 15. GenScript Biotech Corporation
  • 16. KBI Biopharma, Inc.
  • 17. Lonza Group AG
  • 18. Merck Group
  • 19. PromoCell GmbH
  • 20. Rentschler Biopharma SE
  • 21. Samsung Biologics Co., Ltd.
  • 22. Sartorius AG
  • 23. Syngene International Limited
  • 24. Thermo Fisher Scientific Inc.
  • 25. WuXi AppTec Co., Ltd.
  • 26. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. CELL LINE DEVELOPMENT MARKET MULTI-CURRENCY
  • FIGURE 2. CELL LINE DEVELOPMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL LINE DEVELOPMENT MARKET RESEARCH PROCESS
  • FIGURE 4. CELL LINE DEVELOPMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CELL LINE DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CELL LINE DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL LINE DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL LINE DEVELOPMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY HYBRIDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY STEM CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY FINITE CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE CHARACTERIZATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CUSTOM CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INCUBATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY AMPHIBIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA CELL LINE DEVELOPMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA CELL LINE DEVELOPMENT MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA CELL LINE DEVELOPMENT MARKET SIZE, BY CELL LINE SERVICES,